SCHEMBL7085133

SCHEMBL7085133

COc1ccc(C(O)(C(=O)c2ccccc2)c2ccccc2)c(-c2ccc(SC)cc2)c1OC

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 1/20 0.36
CYP1A1 P04798 2/20 0.36
CYP1B1 Q16678 2/20 0.36
CYP1A2 P05177 1/20 0.36
GAA P10253 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.34
FFAR2 O15552 1/20 0.33
POLB P06746 1/20 0.33
HTT P42858 1/20 0.33
KDM4E B2RXH2 1/20 0.33
MAPT P10636 1/20 0.33
ALOX15 P16050 1/20 0.33
MAPK1 P28482 1/20 0.33
HSD17B10 Q99714 1/20 0.33
SRC P12931 1/20 0.33
MAOB P27338 1/20 0.33
AKR1C3 P42330 1/20 0.33
AKR1C2 P52895 1/20 0.33
AKR1C1 Q04828 1/20 0.33
CYP2C9 P11712 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7090546 0.89 CES1 (0.36) CES1GAASMN1; SMN2POLBHTT
SCHEMBL7090214 0.81 CES1 (0.34) CES1CYP1A1CYP1B1CYP1A2SMN1; SMN2
SCHEMBL7084404 0.75 NR3C2 (0.41) CES1GAASMN1; SMN2POLBHTT
SCHEMBL7091315 0.75 CYP2C9 (0.35) CES1GAASMN1; SMN2POLBKDM4E
SCHEMBL7089474 0.73 PPARG (0.39) CES1CYP1A2MAPTMAPK1AKR1C3
SCHEMBL8800962 0.72 ALDH1A1 (0.51) CES1GAAPOLBHTTKDM4E
SCHEMBL7085575 0.71 SMN1; SMN2 (0.40) CES1CYP1A1CYP1B1GAASMN1; SMN2
SCHEMBL7087777 0.71 NOX1 (0.36) POLBMAPK1AKR1C3AKR1C2AKR1C1
SCHEMBL7089413 0.70 DDR1 (0.35) CES1CYP2C9ALDH1A1
SCHEMBL7085175 0.69 DDR1 (0.34) CES1KDM4ECYP2C9ALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030050330-A1 4,5-subtstituted imdazolyl compounds for the treatment of inflammation G.D. SEARLE & CO. 2003-03-13 US disclosed
EP-0772601-B1 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION SEARLE & CO (US) 2002-09-18 EP disclosed
US-6426360-B1 ANTIARTHRITIC AGENTS G D SEARLE & CO. 2002-07-30 US disclosed
EP-1211244-A2 4,5-substitued imidazolyl compounds for the treatment of inflammation G.D. Searle & Co. (US) 2002-06-05 EP disclosed
WO-1996003387-A1 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1996-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030050330-A1 4,5-subtstituted imdazolyl compounds for the treatment of inflammation AHR, HACL2, IRAK2 CES1 374/4885CYP1A1 572/4885CYP1B1 332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.